⚠️ Uptrend Under Pressure Severe risk · 99 · Institutional selling is building — 6 distribution days in the last 25 sessions. · 6 distribution days (SPY) Full briefing → Jul 28
Simple research view

AZN · AstraZeneca PLC

$189.28 latest stored close
Detected setup Flat Base

Watch · Quality 90/100

Ask about AZN

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

Scans / Health Technology / AZN

$AZN

AstraZeneca PLC

AstraZeneca PLC is a mega-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $215B.

Buy · 76 Health Technology Pharmaceuticals: Major stock Stage 2 · Advancing Base 1 Data 1h 1m ago
$189.28 latest close
Council read · 6 methods

Watch — evidence is building

0 buyable · 5 watch · 1 avoid. Review the observed passes and blockers before reading the chart.

Earnings-risk mode

Post-earnings setup

Monday, July 27, 2026 Time not confirmed No sourced report session or clock time

Deterministic evidence

AZN-1.99%
Same completed session window ending 2026-07-08.
CatalystUnavailable Stock reactionNegative Sector reactionUnavailable Opening surgeUnavailable Event riskEarnings-driven
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.
Price $189.28 Jul 08 close
52W High $212.71 -11.0%
52W Low $68.61
Wks Since High 19w
Base Depth -18.4%
Tight Wks 1
Base B1
SMA 50 $184.11
SMA 200 $143.61
Avg Vol 2,039,770
RS Rank 99
RS vs High -18.2%
RS Slope +2.0% ▲
Grp Rank #16/64
ADR% 1.8%
ATR(14) $4.99 (2.6%)
Rel Vol (today) 0.96×
Vol Pace N/A
U/D Vol 0.98
A/D Days 9A / 20D
A/D Rating E
VDU Bars 0/10 d
Power Trend 4d
Earnings past
$68.61
$212.71 84%

AZN Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for AZN.

Create Free Account
Setup Quality B 4/7 signals
Jul 02: 90 (Flat Base)Jul 03: 90 (Flat Base)Jul 06: 92 (Base Breakout)Jul 07: 90 (Flat Base)Jul 08: 91 (Flat Base)Jul 09: 90 (Flat Base)90 Score trend
✓ Stage 2 · Advancing ✗ Power Trend 4d ✗ RS New High ✓ Trend 8/8 ✗ No Pattern ✓ CANSLIM 73.7 (B) ✓ Gatekeeper Base #1 (A)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$AZN · $189.28 · as of 2026-07-08 · multi-factor read
76
/ 100
Buy

Trend · Daily / Weekly / Monthly

Daily ▬ Sideways / consolidating
Weekly ▬ Sideways / consolidating
Monthly ▬ Sideways / consolidating

Moving Averages

50-day$184.11 ↑
100-day$191.12 ↓
200-day$143.61 ↑
Bullish (50 > 200)

RSI (14)

Reading54.0 · Neutral

Neutral — momentum is balanced between buyers and sellers.

MACD (12/26/9)

StateBullish
Histogram+1.189

Bullish — MACD above its signal line and above zero. Histogram contracting.

Bollinger Bands (20,2)

%B / Width72% · 13.1%

Mid-band — no directional band edge in play.

Volume · Buyer vs Seller

Up/Down vol0.98 · Neutral
Rel volume0.96×

Balanced — up/down volume is roughly even; no clear hand. Recent volume is expanding versus its baseline.

Support & Resistance

R · $191.50swing level
R · $207.30swing level
R · $209.93swing level
Price · $189.28now
S · $181.33swing level
S · $174.12swing level
S · $89.34swing level

Fibonacci · Uptrend swing

23.6%$183.52
38.2%$165.47
50.0%$150.88
61.8%$136.28
78.6%$115.51

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for AZN — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Above 200-day MA50/200 bullishRS 97 (leader)
Want this read in a legend's voice? 💬 Ask a Legend about AZN
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 5 of 6 legends are Watching — building, not yet a confirmed buy.
Watch
Minervini B

Trend-template read: 10/12 pass; wait for the soft misses to improve.

Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $189.28, MA150 $163.41, MA200 $143.61
1.2 150-day MA > 200-day MAMA150 $163.41 vs MA200 $143.61
Failing evidence
2. Quarterly EPS growth ≥ 25%+21.7% QoQ
2. Revenue growth ≥ 20% YoY+9.9% YoY
10/12 checks
Avoid
O'Neil D

CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence
L: RS rank ≥ 80 (IBD leadership)RS rank 98
A: Annual earnings & revenue qualityRev +9.9% | ROE 22.3%
Failing evidence
C: Quarterly EPS acceleration ≥ 25%+21.7% QoQ
S: Volume ≥ 40% above average on breakoutVolume ratio 0.96x
4/8 checks
Watch
Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $189.28 vs MA200 $143.61
Failing evidence
Volume expansion above averageVolume ratio 0.96x
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
5/7 checks
Watch
Livermore B

Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$189.28
Relative strengthRS 98
Failing evidence
Volume vs average0.96x
Pivotal point cleared on expanding volumeNot confirmed
4/6 checks
Watch
Darvas B

Box-theory read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$189.28
Relative strengthRS 98
Failing evidence
Volume vs average0.96x
Box top broken on heavy volumeNot confirmed
4/6 checks
Watch
Wyckoff B

Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.

Passing evidence
Price$189.28
Relative strengthRS 98
Failing evidence
Volume vs average0.96x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
4/6 checks
Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

🕯 Latest candle: Shooting Star — Long upper shadow with a small body near the low — sellers rejected higher prices. A caution flag when price is extended above a pivot.

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising
225RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net -6 E
A: 12 D: 18 Net: -665 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini SEPA criteria · 5/7 met
B 5/7 SEPA
Separate score from the 8-point Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ +22%
Revenue growth ≥20% YoY +10%
Gross margin ≥30% 81%
ROE ≥17% 22%
RS rating ≥80 (leadership) 98
Stage 2 uptrend (Weinstein) Stage 2
Within 25% of 52W high -11.0%

Method Playbook

📋 Trade it like Wyckoff EXACT LEVELS · PRO
Minervini O'Neil Livermore Weinstein Darvas Wyckoff
Wyckoff B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro level
Published-method rule: Use the Spring/test, Sign of Strength, creek, or Last Point of Support boundary identified by the active structure.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a completed test or Sign of Strength/Last Point of Support confirmation with improving demand versus supply.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Start below the Spring/test low or structural support whose failure would invalidate the accumulation read.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Raise protection beneath successive Last Points of Support or meaningful higher lows during markup; never loosen it.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on a failed Sign of Strength, support loss, or clear supply-dominant reversal such as an upthrust failure.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →
No active setup in the latest scan — showing last result from 19 days ago. Patterns may no longer be valid. Run a new scan →

Pattern Analysis (historical · 19d ago)

89.8 score
RS Score 98
Trend 8/8
CANSLIM 73.7* (B)
depth pct: 11.7 base days: 51 prior uptrend pct: 112.7 weekly close spread pct: 9.0 vol dried: ✓ validation reason: valid generic setup multi tf reason: weekly trend template 8/8 confirmed
Why This Setup?
Flat Base

Flat Base: 51d base, depth 11.7%, prior uptrend 113%. Pivot $196.64. | Strong trend (8/8) | Top RS (98) | High-confidence pattern (85%) | Stage 2 | Readiness 65/100 (watch) | CANSLIM 73.7 (B)

The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

2/7 universals met
Why these seven? → The Universal Edge

Minervini Trend Template

8/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $189.28 vs SMA150 $163.41 / SMA200 $143.61
SMA 150 above SMA 200 SMA150 $163.41 vs SMA200 $143.61
SMA 200 trending up Slope +10.39 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $184.11
Price above SMA 50 $189.28 vs SMA50 $184.11
30%+ above 52W low +175.9% from $68.61
Within 25% of 52W high -11.0% from $212.71
RS score above 70 RS 98

Fundamentals

52W Range
84%
Mkt Cap SEC
214.9B
EPS QoQ
+22%
Rev YoY
+10%
ROE
22%
Gross Margin
81%
D/E
0.61
EPS TTM
$6.65
P/E TTM
28.4x
Insider
No Buy

Company

Legend AI snapshot
AstraZeneca PLC
AZN · NYSE · Health Technology · Pharmaceuticals: Major
$189.28latest close $214.9Bmarket cap 99RS rank 90setup score
O'Neil · Grade Card
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
B 73.7* CANSLIM * disqualified on C, M
C · Curr. EPS
88
A · Annual EPS
76
N · New Highs
40
S · Supply/Demand
70
L · Leader RS
98
I · Inst. Spons.
100
M · Market
30

Weekly Context

Multi-timeframe signals from weekly bars
W. Trend
8/8
W. RS
98
W. Support
$89.04
W. Resist
$212.71
Weekly Structure

Scan History

Jul 02: 90 (Flat Base)Jul 03: 90 (Flat Base)Jul 06: 92 (Base Breakout)Jul 07: 90 (Flat Base)Jul 08: 91 (Flat Base)Jul 09: 90 (Flat Base)90
Jul 09
Flat Base ✓ Gate
90
Jul 08
Flat Base ✓ Gate
91 0.0%
Jul 07
Flat Base ✓ Gate
90 -2.0%
Jul 06
Base Breakout ✓ Gate
92 -0.5%
Jul 03
Flat Base
90 -0.5%
Jul 02
Flat Base
90 -3.0%

Get the full picture on AZN

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial